AlloVir (ALVR)
(Delayed Data from NSDQ)
$0.79 USD
-0.03 (-4.01%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.78 -0.01 (-0.70%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.79 USD
-0.03 (-4.01%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.78 -0.01 (-0.70%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Zacks News
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
by Zacks Equity Research
Here is how AlloVir, Inc. (ALVR) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)
by Zacks Equity Research
AlloVir, Inc. (ALVR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
5 Stocks With Rising P/E to Bet on for Solid Gains
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Crocs (CROX), AlloVir (ALVR), Arcadia Biosciences (RKDA), The Duckhorn Portfolio (NAPA) and Genuine Parts (GPC).
5 Top-Ranked Stocks With Rising P/E Worth Investing In
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Planet Fitness (PLNT), AlloVir (ALVR), Entergy (ETR), The Duckhorn Portfolio (NAPA) and Genuine Parts (GPC).
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
by Zacks Equity Research
Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.
KalVista (KALV) Surges 15% on Update From Angioedema Study
by Zacks Equity Research
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%
by Zacks Equity Research
Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why
by Zacks Equity Research
AlloVir, Inc. (ALVR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.
Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat
by Zacks Equity Research
Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.
Wall Street Analysts Predict a 281.43% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 281.4% upside potential for AlloVir, Inc. (ALVR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sage and Biogen's NDA for Depression Drug Gets Priority Review
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AlloVir, Inc. (ALVR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8%
by Zacks Equity Research
The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 355.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year.
Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 259.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does AlloVir, Inc. (ALVR) Have the Potential to Rally 251% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 251.2% upside potential for AlloVir, Inc. (ALVR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 447% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel
by Zacks Equity Research
The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections
by Zacks Equity Research
AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.